Evidence map›Paper›PMID 37298418›Full record

ArticleInternational journal of molecular sciences2023

Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.

Elisabetta Vulpis, Luisa Loconte, Chiara Cassone, Fabrizio Antonangeli, Giulio Caracciolo, Laura Masuelli, Francesca Fazio, Maria Teresa Petrucci, Cinzia Fionda, Alessandra Soriani and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Elisabetta VulpisLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.
Luisa LoconteLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.
Chiara CassoneLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.
Fabrizio AntonangeliInstitute of Molecular Biology and Pathology, National Research Council (CNR), 00185 Rome, Italy.ORCID 0000-0002-6369-2249
Giulio CaraccioloDepartment of Molecular Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-8636-4475
Laura MasuelliDepartment of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
Francesca FazioDepartment of Cellular Biotechnologies and Hematology, "Sapienza" University of Rome, 00161 Rome, Italy.
Maria Teresa PetrucciDepartment of Cellular Biotechnologies and Hematology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0003-0688-4882
Cinzia FiondaLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.
Alessandra SorianiLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.ORCID 0000-0001-5461-9026
Cristina CerboniLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.ORCID 0000-0002-0371-9534
Marco CippitelliLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.ORCID 0000-0002-9620-538X
Angela SantoniLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.
Alessandra ZingoniLaboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.ORCID 0000-0003-0906-1566
Istituto Pasteur · ITSapienza University of Rome · ITInstitute of Molecular Biology and Pathology · ITIstituto Neurologico Mediterraneo · IT

Funding

Sapienza University of Rome RG12218166D295B0 and RG11916B7F06EC21
6 · The paper itself

Abstract

Natural Killer (NK) cells are innate cytotoxic lymphoid cells that play a crucial role in cancer immunosurveillance. NKG2D is an activating receptor that binds to MIC and ULBP molecules typically induced on damaged, transformed, or infected cells. The secretion of NKG2D ligands (NKG2DLs) through protease-mediated cleavage or in an extracellular vesicle (EV) is a mode to control their cell surface expression and a mechanism used by cancer cells to evade NKG2D-mediated immunosurveillance. EVs are emerging as important players in mediating cell-to-cell communication due to their ability to transfer biological material to acceptor cells. Herein, we investigated the spreading of NKG2DLs of both MIC and ULBP molecules through the EV-mediated cross-dressing on multiple myeloma (MM) cells. We focused our attention on two MICA allelic variants, namely MICA*008 and MICA*019, representing the prototype of short and long MICA alleles, respectively, and on ULBP-1, ULBP-2, and ULBP-3. Our findings demonstrate that both ULBP and MICA ligands can be acquired from tumor cells through EVs enhancing NK cell recognition and killing. Moreover, besides MICA, EVs expressing ULBP-1 but not ULBP-2 and 3 were detected in bone marrow aspirates derived from a cohort of MM patients. Our findings shed light on the role of EV-associated MICA allelic variants and ULBP molecules in the modulation of NKG2D-mediated NK cell immunosurveillance in the tumor microenvironment. Moreover, the EV-mediated transfer of NKG2DLs could suggest novel therapeutic approaches based on the usage of engineered nanoparticles aimed at increasing cancer cell immunogenicity.

Indexed as

Extracellular VesiclesMultiple MyelomaBandagesCell DeathHistocompatibility Antigens Class IHumansKiller Cells, NaturalLigandsNK Cell Lectin-Like Receptor Subfamily KTumor MicroenvironmentHistocompatibility Antigens Class ILigandsNK Cell Lectin-Like Receptor Subfamily Kextracellular vesiclesmultiple myelomanatural killer cellsNKG2D

Identifiers

PMID37298418
PMCPMC10253317
OpenAlexW4380225132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.